We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$9.32B
AUM Growth
+$2.47B
Cap. Flow
+$393M
Cap. Flow %
4.22%
Top 10 Hldgs %
43.12%
Holding
161
New
36
Increased
24
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$348M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$229M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$100M
4
CCCC icon
C4 Therapeutics
CCCC
+$91.6M
5
KRON
Kronos Bio
KRON
+$87.2M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$190M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$112M
3
IMMU
Immunomedics Inc
IMMU
+$77.6M
4
BPMC
Blueprint Medicines
BPMC
+$61.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 85.2%
2 Financials 0.33%
3 Industrials 0.29%
4 Materials 0.22%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
76
DELISTED
NanoString Technologies, Inc.
NSTG
$22.6M 0.24%
+337,800
New +$16.9M
PCVX icon
77
Vaxcyte
PCVX
$7.65B
$22.6M 0.24%
850,000
– –
GERN icon
78
Geron
GERN
$898M
$21.4M 0.23%
13,461,538
– –
PNT
79
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$20.9M 0.22%
1,500,000
– –
AMRS
80
DELISTED
Amyris Inc.
AMRS
$20.6M 0.22%
3,333,332
– –
VRNA
81
DELISTED
Verona Pharma
VRNA
$20.2M 0.22%
2,888,889
– –
WVE icon
82
Wave Life Sciences
WVE
$1.12B
$19.7M 0.21%
2,500,000
– –
CYPH
83
Cypherpunk Technologies Inc
CYPH
$64M
$19.1M 0.2%
847,650
– –
VTRS icon
84
Viatris
VTRS
$20.8B
$18.8M 0.2%
1,004,419
– –
RGEN icon
85
Repligen
RGEN
$6.91B
$18.7M 0.2%
+97,500
New +$17.7M
SCYX icon
86
SCYNEXIS
SCYX
$37.4M
$18.4M 0.2%
+300,000
New +$14.1M
HRMY icon
87
Harmony Biosciences
HRMY
$2.08B
$18.2M 0.2%
502,622
+67,245
+15% +$2.71M
NBTX
88
Nanobiotix
NBTX
$1.92B
$18.1M 0.19%
+1,100,000
New +$19M
DRNA
89
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$17.6M 0.19%
800,000
– –
DBVT
90
DBV Technologies
DBVT
$813M
$17.3M 0.19%
659,551
-21,147
-3% -$468K
CTMX icon
91
CytomX Therapeutics
CTMX
$690M
$16.9M 0.18%
2,577,043
– –
MORF
92
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$16.3M 0.18%
487,000
– –
LGVW.U
93
DELISTED
Longview Acquisition Corp. Units, each consisting of one share of Class A common stock, and one-thir
LGVW.U
$15.2M 0.16%
700,000
– –
TARA icon
94
Protara Therapeutics
TARA
$214M
$14.7M 0.16%
608,544
– –
AMWL icon
95
American Well
AMWL
$180M
$13.3M 0.14%
26,250
+3,500
+15% +$2.03M
PPH icon
96
PUT
VanEck Pharmaceutical ETF
PPH
$985M
$13.3M 0.14%
200,000
– –
FBRX icon
97
Forte Biosciences
FBRX
$1.57B
$12.7M 0.14%
+14,000
New +$13.2M
TSHA icon
98
Taysha Gene Therapies
TSHA
$1.61B
$12.5M 0.13%
470,440
– –
TCRR
99
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$12.4M 0.13%
400,000
– –
HCAT icon
100
Health Catalyst
HCAT
$160M
$12M 0.13%
276,084
-15,000
-5% -$553K
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Perceptive Advisors held 161 positions worth $9.32B, up 36% from $6.85B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors deployed $393M of net new capital in Q4 2020, opening 36 new positions and adding to 24 existing holdings. Its largest new stake was Invitae Corporation: 7,284,466 shares worth $305M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $36.5M trimmed.

  • Perceptive Advisors's largest Q4 2020 buy was Invitae Corporation: 7,284,466 shares worth $305M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $55.8M increase.
  • Perceptive Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $36.5M.
  • Perceptive Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $190M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $9.32B portfolio in Q4 2020.
  • Perceptive Advisors opened 36 new positions and closed 22 in Q4 2020.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $9.32B.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.